following a full submission assessed under the end of life and orphan equivalent medicine process:
venetoclax (Venclyxto ®) is accepted for use within NHSScotland.
Indication under review: in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
In a phase III study, treatment with venetoclax in combination with azacitidine significantly improved overall survival and remission rate when compared with azacitidine alone.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- venetoclax (Venclyxto)
- SMC ID:
In combination with a hypomethylating agent (HMA) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy (IC).
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 11 April 2022